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Pancreatic cancer is predominantly lethal, and is primarily treated using gemcitabine, with increasing 
resistance. Therefore, novel agents that increase tumor sensitivity to gemcitabine are needed. Histone 
deacetylase (HDAC) inhibitors are emerging therapeutic agents, since HDAC plays an important role 
in cancer initiation and progression. We evaluated the antitumor effect of a novel HDAC inhibitor, 
CG200745, combined with gemcitabine/erlotinib on pancreatic cancer cells and gemcitabine-resistant 
pancreatic cancer cells. Three pancreatic cancer-cell lines were used to evaluate the antitumor effect 
of CG200745 combined with gemcitabine/erlotinib. CG200745 induced the expression of apoptotic 
proteins (PARP and caspase-3) and increased the levels of acetylated histone H3. CG200745 with 
gemcitabine/erlotinib showed significant growth inhibition and synergistic antitumor effects in vitro. 
In vivo, gemcitabine/erlotinib and CG200745 reduced tumor size up to 50%. CG200745 enhanced the 
sensitivity of gemcitabine-resistant pancreatic cancer cells to gemcitabine, and decreased the level of 
ATP-binding cassette-transporter genes, especially multidrug resistance protein 3 (MRP3) and MRP4. 
The novel HDAC inhibitor, CG200745, with gemcitabine/erlotinib had a synergistic anti-tumor effect on 
pancreatic cancer cells. CG200745 significantly improved pancreatic cancer sensitivity to gemcitabine, 
with a prominent antitumor effect on gemcitabine-resistant pancreatic cancer cells. Therefore, 
improved clinical outcome is expected in the future.
Pancreatic cancer is the most lethal cancer with poor prognosis. Patients with locally advanced disease have a 
median survival time of 8–12 months, and patients with distant metastases have significantly worse outcomes, 
with a median survival time of only 3–6 months1. At present, gemcitabine-based regimens are considered stand-
ard treatment for pancreatic cancer patients. Recently, gemcitabine plus nab-paclitaxel showed minimal improve-
ments in overall survival with a median survival approaching one year in patients with advanced pancreatic 
cancer2. Despite these advances in gemcitabine-based treatment, the number of pancreatic cancer-related deaths 
and chemotherapy refractory pancreatic cancer has continued to increase3. Since the resistance of pancreatic can-
cer negatively affects the therapeutic effects of gemcitabine, agents that increase tumor sensitivity and overcome 
drug resistance to gemcitabine are needed.
Histone deacetylase (HDAC) inhibitors are the most developed anti-cancer drugs targeting epigenetic modu-
lation. In normal cells, histone acetylation is precisely controlled by histone acetyl transferase (HAT) and HDAC. 
However, hyper-acetylation of oncogenes or hypo-acetylation of tumor suppressor genes is frequently observed 
in cancer cells4. HDAC inhibitors acetylate the lysine residues at the histone N-terminal tail, and loosen the 
association of histones with DNA, thereby inducing the expression of genes related to tumor suppression and dif-
ferentiation. Therefore, HDAC inhibition offers potential as an effective cancer treatment5,6. To date, two HDAC 
inhibitors, vorinostat and romidepsin, have been approved by the Food and Drug Administration (FDA) for 
the treatment of cutaneous T-cell lymphoma. Regarding pancreatic cancer, previous studies showed that HDAC 
inhibitors show in vitro and in vivo anti-tumor effects7–10.
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CG200745, (E)-N(1)-(3-(dimethylamino)propyl)-N(8)-hydroxy-2-((naphthalene-1-loxy) methyl)
oct-2-enediamide, is a recently developed HDAC inhibitor4,11,12. Similar to other inhibitors, such as vorinostat 
and belinostat, the novel HDAC inhibitor, CG200745, is an intravenous hydroxamate-based pan-HDAC inhib-
itor. Its inhibitory effect on cell growth has been demonstrated in several types of cancer cells, including pros-
tate cancer, renal cell carcinoma, and colon cancer in mono- and combinational-therapy with other anticancer 
drugs4,11–13. CG200745 was five times more effective than vorinostat in acetylating histone H3 in colon cancer-cell 
lines, and induced the acetylation of the tumor suppressor, p53, and cancer cell death11.
Combination therapy using gemcitabine/erlotinib is an approved standard chemotherapy in patients with 
advanced pancreatic cancer, but has marginal therapeutic benefits14. To improve the therapeutic results, we inves-
tigated the anti-tumor effect of CG200745 combined with gemcitabine/erlotinib in pancreatic cancer cells. We 
also evaluated whether CG200745 could overcome the resistance to gemcitabine in human gemcitabine-resistant 
pancreatic cancer cells.
Results
Effect of CG200745 on growth inhibition and cell death in pancreatic cancer cells. As shown 
in Fig. 1A, CG200745 dose-dependently decreased pancreatic cancer cell viability. To determine the inhibitory 
effects of CG200745 on cell proliferation, we measured the IC50 of CG200745 in pancreatic cancer cells. BxPC3 
were more sensitive to the growth-inhibitory effect of CG200745 (IC50; 2.4 μ M) than Cfpac-1 and HPAC (IC50; 
10.7 and 7.4 μ M, respectively). To assess the effects of CG200745 on HDACs in pancreatic cancer cells, we meas-
ured histone H3 acetylation levels. Treatment of pancreatic cancer cells with the IC50 of CG200745 caused a 
significant increase in histone H3 acetylation within 24 h of treatment (Fig. 1B). Doses of erlotinib and CG200745 
equivalent to IC 20~30 were selected to minimize individual cytotoxic effect and know the combinatory anti-
cancer effect on the pancreatic cancer cell lines, respectively (Fig. 1 and Supplementary Fig. 1). The effect of 
CG200745 on pancreatic cancer cell apoptosis was also tested. Western blot analysis indicated that CG200745 
increased the expression of pro-apoptotic proteins, BAX, and p21 (Fig. 1B).
Synergistic inhibitory and apoptotic effect of CG200745 combined with gemcitabine/erlotinib 
in pancreatic cancer cells. BxPC3, Cfpac-1, and HPAC cell lines were treated with gemcitabine, erlotinib, 
Figure 1. Anti-proliferative and pro-apoptotic activities of CG200745 against pancreatic cancer cells. 
(A) Cell viability curve based on the CG200745 concentration in three pancreatic cancer cell lines. CG200745 
inhibits the proliferation of pancreatic cancer cells. (B) CG200745 induces histone-H3 acetylation and increases 
BAX and p21 expression related to apoptosis.
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and CG200745. The results from the cell viability indicated that the anti-proliferative effect of CG200745 with 
gemcitabine/erlotinib was significantly higher than that of other combinations (Fig. 2 and Supplementary Fig. 2). 
Western blot analysis showed the apoptotic protein, cleaved caspase-3, in a triple combination line. A low 
CG200745 concentration, with a combination of gemcitabine or erlotinib, significantly increased the antitumor 
effect, and was most effective when combined with both regimens.
Flow cytometry was performed to examine the apoptotic rate of BxPC3 cells 72 h after CG200745 administra-
tion by using the Annexin V-FITC/PI double staining method (Fig. 3). The results of flow cytometry showed that 
CG200745 treatment increased the number of Annexin V-positive BxPC3 cells, indicating apoptosis induction. 
Notably, cell exposure to CG200745 resulted in enhanced accumulation of autophagic, late apoptotic cells. Flow 
cytometry results showed that CG200745 combined with gemcitabine/erlotinib treatment increased the number 
of Annexin V-positive BxPC cells, indicating apoptosis activation. CG200745 sensitized pancreatic cancer cells to 
the anti-proliferative effects of gemcitabine and erlotinib. The interaction between CG200745 and gemcitabine/
erlotinib was further analyzed using the Chou–Talalay method15, to determine whether this combination exhib-
ited additive or synergistic cytotoxicity. Using CompuSyn software, we calculated the Combination index (CI) 
according to concentrations of CG200745, gemcitabine, and erlotinib, which revealed that this combination was 
synergistic in the three cell lines. Moreover, the CIs of triple combinations showed better synergism than that of 
other combinations (Supplementary Table 1).
Combination effect of CG200745 with gemcitabine/erlotinib in a xenograft model. As shown 
in Fig. 4, the BxPC3 xenograft growth in nude mice was dramatically inhibited by the co-administration of 
CG200745 and gemcitabine/erlotinib. Combined gemcitabine/erlotinib and CG200745 reduced the tumor vol-
ume up to 50% by 3 weeks in the BxPC3 xenograft model.
Growth inhibition by CG200745 in gemcitabine-resistant pancreatic cancer cells. 
Gemcitabine-resistant cells were very insensitive to the growth-inhibitory effect of gemcitabine. The IC50 of 
gemcitabine in gemcitabine-resistant cells was 0.595 and 7.654 μ M, which was 24.5-fold and 7.9-fold higher 
than that of parent cell lines Cfpac-1 and HPAC, respectively. However, the treatment with CG200745 in 
gemcitabine-resistant pancreatic cancer cells eliminated the chemo-resistance (Supplementary Fig. 3). The IC50 
Figure 2. Synergistic effect of CG200745 combined with gemcitabine/erlotinib in pancreatic cancer 
cell lines (BxPC3). The doses of erlotinib and CG200745 were equivalent to IC 20~30. (A) The growth of 
pancreatic cells was analyzed via an MTT assay after treatment with various concentrations of gemcitabine 
over a time-course (0–72 h). The anti-proliferative effect of CG200745 with gemcitabine/erlotinib is more 
enhanced than the effect of gemcitabine/erlotinib without CG200745 in pancreatic cancer cells. (B) Western 
Blot analysis to investigate the pancreatic cancer cell apoptosis and analyze the molecular pathway related to 
CG200754. CG200745 combined with gemcitabine/erlotinib induces apoptosis through caspase-3 activation. 
(C) Immunofluorescent staining of cleaved caspase-3 expressing cells. Fluorescence signals specific to cleaved 
caspase-3 antibodies were visualized as green, and DAPI (blue) was used to indicate nuclei. * or **Indicates 
significant differences compared with the control (p < 0.05 or p < 0.01). G, gemcitabine; CG, CG200745; E, 
erlotinib.
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of CG200745 in gemcitabine-resistant cells was 9.8 and 6.8 μ M, which was 0.8-fold and 0.9-fold lower than that 
of parent cell lines Cfpac-1 and HPAC, respectively. CG200745 sensitized gemcitabine-resistant pancreatic can-
cer cells to the anti-proliferative effects of gemcitabine and erlotinib. The anti-proliferative effect of the triple 
combination was most effective in gemcitabine-resistant Cfpac-1- and HPAC-cell lines and CIs revealed that this 
combination was strongly synergistic (Fig. 5).
The agarose gel electrophoresis of the MRP family revealed that CG200745 treatment decreased the mRNA 
levels of ABC transporter genes, especially MRP3 and MRP4 (Fig. 6A and B). Western blot analysis showed sig-
nificantly reduced MRP4 expression in gemcitabine-resistant pancreatic cancer-cell lines (Fig. 6C and D). It was 
hypothesized that gemcitabine sensitivity could be increased in combination with CG200745. These preclinical 
results show that combined treatment of CG200745 and gemcitabine/erlotinib potentiated the anti-tumor effects 
in gemcitabine-resistant pancreatic cancer cells.
Discussion
Aberrant expression of HDACs represents an attractive therapeutic target for pancreatic cancer. Since HDAC 
inhibitors can reactivate epigenetically silenced genes, they could be used in pancreatic cancer as anticancer 
agents. Previously, several HDAC inhibitors have been studied for the inhibition of pancreatic cancer cells. 
Trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA) strongly inhibited the growth of pancreatic 
cancer cells by inducing cell-cycle arrest and apoptosis16. Recently, the synergistic effects of HDAC inhibitors and 
conventional chemotherapeutic agents have been studied17, which showed that a combination of gemcitabine 
and HDAC inhibitors potently enhanced gemcitabine-mediated growth inhibition and apoptosis in pancreatic 
cancer cells9,18,19. To the best of our knowledge, this is the first study to show the anticancer effects of a new HDAC 
inhibitor, CG200745, on pancreatic cancer cells. In the present study, CG200745 combined with conventional 
chemotherapeutic regimens, gemcitabine/erlotinib, dramatically inhibited pancreatic cancer-cell proliferation 
in vitro and in vivo. Furthermore, CG200745 enhanced the sensitivity of gemcitabine-resistant pancreatic cancer 
cells to gemcitabine treatment.
A limited efficacy in solid tumors and undesirable adverse reactions of HDACIs were reported in previous 
clinical studies20. For example, Richards et al.21 showed the anticancer effect of the combination of the HDAC 
inhibitor, CI-994, and gemcitabine in pancreatic cancers; patients receiving CI-994 combined with gemcitabine 
had a higher incidence of grade 3/4 adverse events such as thrombocytopenia, anemia, and leukopenia than those 
treated with only gemcitabine. However, CG200745 was well tolerated at the tested doses with no dose-limiting 
toxicities in the first human study. Only grade 3/4 hematologic toxicities were reported, such as anemia and 
Figure 3. The FACS analysis indicates that CG200745 induces apoptosis of pancreatic cancer-cell lines. The 
doses of erlotinib and CG200745 were equivalent to IC 20~30. The apoptosis rate of BxPC3 cells cultured 72 h 
after drug administration in the (A) control, (B) 0.01 μ M gemcitabine, (C) 0.01 μ M gemcitabine + 0.288 μ M  
CG200745, (D) 0.01 μ M gemcitabine + 0.015 μ M erlotinib, (E) 0.01 μ M gemcitabine + 0.288 μ M 
CG200745 + 0.015 μ M erlotinib. Annexin V-FITC/PI double staining; Q1, autophagic cell death; Q2, late 
apoptotic cells; Q3, normal cells; Q4, early apoptotic cells.
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Figure 4. CG200745 inhibits the growth of pancreatic tumors in nude mice. (A) Relative tumor volume with 
gemcitabine, erlotinib, and CG200745 treatments. (B) Relative tumor weight with gemcitabine, erlotinib, and 
CG200745 treatments. Cell line: BxPC-3; animal: Balb/c nude mouse, female, 6 w; dosing schedule: 3 weeks; 
CG200745: 30 mg/kg, IP, daily; erlotinib: 50 mg/kg, PO, daily; femcitabine, Gem: 20 mg/kg, IP, day 1, 4, 7, 10, 13, 
16, 19.
Figure 5. Synergistic effect of CG200745 in combination with gemcitabine/erlotinib in gemcitabine-resistant 
pancreatic cancer cells (A, Cfpac-1; B, HPAC). The anti-proliferative effect of CG200745 combined with 
gemcitabine/erlotinib is more than the effect of gemcitabine/erlotinib without CG200745 in gemcitabine-
resistant pancreatic cancer cells. * or **Indicates significant differences compared with control (p < 0.05 or 
p < 0.01). G, gemcitabine; CG, CG200745; E, erlotinib.
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neutropenia, which did not last more than one week. Other toxicities included Grade 1/2 mild fatigue and 
anorexia13.
Gemcitabine-based regimens remain a major chemotherapy for pancreatic cancer, but the resistance to gem-
citabine has negatively affected the overall survival in cancer patients. Drug resistance is attributable to several 
processes occurring in neoplastic cells. One of these processes is decreased drug accumulation within cancer 
cells because of an increased drug efflux. Specifically, the ATP-binding cassette transporter family C (ABCC) 
is responsible for mediating multidrug resistance22. Human ABCC consists of 12 members, 9 of which com-
prise a group of multidrug-resistant proteins (MRP1–MRP9, ABCC1–ABCC6, and ABCC10–ABCC12). In 
the present study, CG200745 decreased the mRNA transcripts and its corresponding protein for MRP4 in vitro. 
Therefore, CG200745 controlled the drug efflux and sensitivity in gemcitabine-resistant pancreatic cancer cells. 
Improvement of resistance to gemcitabine allows this drug to be used more effectively to treat pancreatic cancer.
The HDAC family is a multiclass consisting of 18 HDACs divided into four subgroups by cell localization, role, 
and structure: class I including HDAC 1, 2, 3, and 8 (localized in the nucleus); class II HDACs including 4, 5, 6, 
7, 9, and 10 (localized in both the nucleus and cytoplasm); class III HDACs consists of sirtuins (1–7); and class 
IV includes HDAC 1123. Similar to the overexpression of HDAC1 in gastric cancer, and HDAC2 and HDAC3 in 
colon cancer, HDAC7 is over-expressed in pancreatic cancer8,24. HDAC7 is also an important regulator in can-
cer25. Approximately 81% of the PDAC tissue samples displayed increased HDAC7 mRNA and protein expres-
sions. Therefore, previous studies showed that HDAC7 could be critical in tumor growth and metastasis, and a 
clinically beneficial biomarker for pancreatic cancer diagnosis and prognosis8,24. In the present study, high levels 
of HDAC7 mRNA and protein were detected in pancreatic cancer cells (Supplementary Fig. 4). The inhibitory 
effect of our novel compound on HDAC7 in pancreatic cancer cells was considerable.
In Cfpac cell, histone acetylation decreased in 48 and 72 h gradually with decreased expression of p21 and 
BAX than two other cell lines. When we re-tested the Western Blot for histone acetylation in Cfpac-1 cell, the 
expression of histone acetylation was decreased like the previous result. But, the pattern of p21 and BAX expres-
sion was similar with other cell lines (Supplementary Fig. 5). The difference of histone acetylation expression 
depends on the different characteristics of pancreatic cancer cell lines. The difference of genetic background for 
3 pancreatic cancer cell lines used in this study may be one of the reasons26. In a previous study, Western Blot 
analysis showed different expression pattern of histone acetylation in 2 patients. In the case of patient 01, histone 
acetylation decreased in 24 and 48 h, but the expression of histone acetylation increased in 24 and 48 h in another 
patient. According to pancreatic cancer cell lines, the extent or timing of histone acetylation expression was dif-
ferent27. In the present study, Cfpac-1 cell lines seem to respond for histone acetylation rapidly compared to other 
cell lines.
In conclusion, the novel HDAC inhibitor, CG200745, showed an antitumor effect in three types of pancre-
atic cancer cell lines and synergized the antitumor effect of gemcitabine and erlotinib, which are conventional 
chemotherapeutic regimens for pancreatic cancer cells. We also showed that the CG200745 combined treat-
ment induced cell death in gemcitabine-resistant cells, suggesting that CG200745 can overcome gemcitabine 
resistance. Resolving the problem of drug resistance to conventional therapies is a key factor for improving 
Figure 6. Agarose gel electrophoresis of the MRP family members indicates mRNA expression in 
gemcitabine-resistant pancreatic cancer cells. CG200745 treatment decreases mRNA levels of ABC 
transporter genes, especially MRP3 and MRP4 (A,C: Cfpac-1; B,D: Hpac). Western blot analysis of MRP4 
expression in gemcitabine resistant cells after CG200745 treatment.
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pancreatic cancer prognosis. Our data provided evidence that CG200745 could potentially improve the treatment 
of gemcitabine-resistant pancreatic cancer. CG200745 combined with standard gemcitabine-based chemotherapy 
could be used as a successful combination therapy in the future.
Methods
Chemicals. CG200745 was provided by CrystalGenomics Inc. (Seoul, Rep. Korea)11,12. A 50-mM stock solu-
tion for biological assays was prepared in dimethyl-sulfoxide (DMSO) and stored at − 20 °C until use. Erlotinib 
was purchased from ApexBio (ApexBio Technology, Houston, TX, USA), and gemcitabine was supplied by Eli 
Lilly Korea (Seoul, Korea).
Cell lines. Three pancreatic cancer-cell lines, BxPC3, Cfpac-1, and HPAC, were purchased from the American 
Type Culture Collection (ATCC, Manassas, VA, USA). BxPC-3 cells were grown in RPMI1640 (Invitrogen Gibco, 
Grand Island, NY, USA) with 10% fetal bovine serum (FBS; Hyclone, Logan, Utah, USA), CFPAC-1 cells were 
grown in IMDM (Invitrogen Gibco) with 10% FBS (Hyclone), and HPAC cells were grown in DMEM/F12 
(Invitrogen Gibco) with 10% FBS (Hyclone). Cells were maintained in a humidified incubator with 5% CO2 at 
37 °C.
Cell viability assay. Cells were seeded at 3~5 × 103/well in 96 well plates and exposed to various concentra-
tions of compounds for 72 h. Cell viability effects of CG200745, gemcitabine, and erlotinib were assessed by the 
3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT; Amresco, Solon, OH, USA) assay. IC50 val-
ues were reached when cell growth was inhibited at 50% of the DMSO control. Values are the means of triplicate 
wells from three independent experiments for each drug concentration.
Western blotting. Cells were lysed in a lysis buffer containing 70 mM glycerophosphate (pH 7.2), 0.6 mM 
Na vanadate, 2 mM MgCl2, 1 mM EGTA, 1 mM DTT, 0.5% Triton X-100, 0.2 mM phenylmethylsulfonyl fluo-
ride (PMSF), and 1× complete protease inhibitor (Roche Applied Science, Nutley, NJ, USA). Protein (25 μ g) 
was resolved on SDS-polyacrylamide gels and transferred to polyvinylidene difluoride (PVDF) membranes 
(Immobilon-P, Millipore, Bedford, MA, USA). The membranes were blocked in 5% (w/v) nonfat dry milk 
(Bio-Rad Laboratories, Inc., Hercules, CA, USA) and incubated with the following primary antibodies: mouse 
monoclonal anti-HDAC1, mouse monoclonal anti-HDAC2, mouse monoclonal anti-HDAC3, rabbit mono-
clonal anti-HDAC4, rabbit monoclonal anti-HDAC6, rabbit polyclonal anti-phospho-AKT, rabbit polyclonal 
anti-phospho-ERK (Cell Signaling Technology, Inc., Danvers, MA, USA), mouse monoclonal anti-HDAC7, 
rabbit polyclonal anti-EGFR, rabbit polyclonal anti-acetylated histone h3, rabbit polyclonal anti-cmet, mouse 
monoclonal anti-caspase3, rabbit polyclonal anti-p21, rabbit polyclonal anti-BAX, rabbit polyclonal anti-AKT, 
rabbit polyclonal anti-ERK, mouse monoclonal anti-MRP4, and mouse monoclonal anti-GAPDH (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA). After incubation with appropriate horseradish peroxidase-conjugated 
secondary antibodies (Santa Cruz Biotechnology), immunoblots were developed with the West Pico 
Chemiluminescent substrate (Thermo Scientific, Rockford, IL, USA).
Semi-quantitative RT-PCR. Total RNA was extracted using an RNeasy mini kit (QIAGEN, Hilden, 
Germany), and cDNA was synthesized using a Superscript II system (Invitrogen) according to manufacturer’s 
protocols. Beta-actin (ACTB) was used as a reference gene. The primers are listed in Supplementary Table 2.
Immunofluorescence. Cells were grown on coverslips and treated with indicated concentrations of com-
pounds for 48 h. Cells were fixed with 4% paraformaldehyde and incubated with blocking buffer (1 × PBS/5% 
normal donkey serum/0.3% Triton X-100). Cells were stained with rabbit polyclonal anti-cleaved caspase-3 
(1:400, Cell Signaling Technology, Inc.) overnight at 4 °C. Stained cells were incubated with goat anti-rabbit Alexa 
488-conjugated secondary antibody (Jackson ImmunoResearch Inc., West Grove, PA, USA) for 1 h. Nuclei were 
labeled with 4′ ,6-diamidino-2-phenylindole (DAPI). The stained cells were analyzed on an Olympus BX51 micro-
scope and images were captured using an Olympus DP71 camera (Olympus America Inc., Center Valley, PA, 
USA).
Apoptosis. Apoptosis was detected by flow cytometry through Annexin V-FITC/propidium iodide (PI) 
staining. Cells (2 × 105 cells per well) were seeded on 6 well plates plates and incubated overnight at 37 °C. The 
compound was added and cells were incubated for a further 72 h. Trypsinized cells were harvested, with 100 μ l 
1× binding buffer. Harvested cells were incubated with 1 μ g/ml FITC-labeled Annexin V (BD Biosciences, San 
Diego, CA) and 2.5 μ g/ml PI at room temperature of 25 °C for 15 min in the dark. Flow cytometric measurement 
of the stained cells was performed with BD LSRII (BD Bioscience, San Jose, CA).
Xenograft mouse model. Experiments carried out using 6-week-old male BALB/c nude mice (Japan SLC, 
Inc., Japan) were approved by the Institutional Animal Care and Use Committee (IACUC) of Biotoxtech Co., Ltd. 
based on the Animal Protection Act. All experiments were performed in accordance with relevant guidelines 
and regulations. Exponentially grown BxPC3 cells (5 × 106 cells/mouse) were s.c. injected into the right flank. 
Treatment started two weeks after the tumor implant, when tumors reached a volume of approximately 100 mm3. 
Gemcitabine (20 mg/kg) was administered i.p. for three weeks (day 1, 4, 7, 10, 13, 16, 19). Erlotinib (50 mg/kg) 
was administered p.o. daily for three weeks. CG200745 (30 mg/kg) was administered i.p. daily for 3 weeks. Tumor 
formation was monitored twice a week by measuring the width and length of the mass, and tumor volume (TV) 
was calculated using the formula ‘TV (mm3) = (L × W2)/2’, with L as the largest and W as the smallest diameters. 
Animals were sacrificed after three weeks from the first administration.
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Gemcitabine-resistant pancreatic cancer-cell lines. Gemcitabine-resistant pancreatic cancer cells 
were established by escalating doses of gemcitabine serially in HPAC and CFPAC-1 cells28. Initially, cells were 
cultured for 72 h with IC50 of gemcitabine with a defined drug-free interval. As cells adapted to the dose, the 
gemcitabine concentration was serially doubled. Finally, after cells recovered from 10 μ M gemcitabine treatment, 
100 μ M of the drug was added to the medium to eradicate most of the cell population.
Combination studies. The effectiveness of chemotherapeutic agents used in this study in combination, was 
analyzed using CompuSyn software15,29. CI values were calculated to confirm synergy. CI < 0.9 indicates synergis-
tic effects, CI between 0.9 and 1.1 indicates addictive effects, and CI > 1.1 indicates antagonistic effects.
Statistics. Statistical analyses were performed using SPSS 18.0 software. All values were expressed as the 
mean ± standard deviation. Comparisons between two groups were analyzed using t-tests. Values of P < 0.05 
were considered significant.
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